Journal
BIOCONJUGATE CHEMISTRY
Volume 21, Issue 1, Pages 5-13Publisher
AMER CHEMICAL SOC
DOI: 10.1021/bc9002019
Keywords
-
Ask authors/readers for more resources
Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic molecules, thereby taking advantage of the best characteristics of both components. Along with the development of the mAbs and cytotoxins, the design of chemical linkers to covalently bind these building blocks is making rapid progress but remains challenging. Recent advances have resulted in linkers having increased stability in the bloodstream while allowing efficient payload release within the tumor cell.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available